公开(公告)号：US20140065135A1

公开(公告)日：2014-03-06

申请号：US13954796

申请日：2013-07-30

Applicant: Genentech, Inc.

Inventor： Bryan Irving ,  Henry Chiu ,  Heather Maecker ,  Sanjeev Mariathasan ,  Sophie M. Lehar ,  Yan Wu ,  Jeanne Cheung

IPC: C07K16/28 ,  A61K45/06 ,  A61K39/395 ,  A61K39/00

CPC classification number: C07K16/2827 ,  A61K31/7068 ,  A61K39/00 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/1063 ,  C07K16/22 ,  C07K16/28 ,  C07K16/30 ,  C07K16/3046 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/71 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2317/92 ,  Y02A50/41 ,  Y02A50/412 ,  Y02A50/423 ,  Y02A50/489 ,  Y02A50/492 ,  A61K2300/00

Abstract: The present application relates to methods of using anti-PD-L1 antibodies to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.

Abstract translation: 本申请涉及使用抗PD-L1抗体来增强T细胞功能以上调细胞介导的免疫应答和治疗T细胞功能障碍（包括感染（例如急性和慢性））和肿瘤免疫的方法。

公开(公告)号：US20250044288A1

公开(公告)日：2025-02-06

申请号：US18717336

申请日：2022-12-07

Applicant: GENENTECH, INC.

Inventor： Darya Yuryevna Orlova ,  Mayra Cruz Tleugabulova ,  Martine Abraham Darwish ,  Jeanne Cheung

IPC: G01N33/557 ,  G01N33/569 ,  G01N33/58

Abstract: Compositions, systems and methods for quantifying binding rate kinetics for receptor molecules and MHC molecules are provided. The quantitative data produced can be of an accuracy and quantity suitable for generating predictive models. More specifically, assays described herein can accommodate analysis of large varieties of MHC associated peptides.

公开(公告)号：US09920123B2

公开(公告)日：2018-03-20

申请号：US15335278

申请日：2016-10-26

Applicant: Genentech, Inc.

Inventor： Bryan Irving ,  Henry Chiu ,  Heather Maecker ,  Sanjeev Mariathasan ,  Sophie M. Lehar ,  Yan Wu ,  Jeanne Cheung

IPC: A61K39/00 ,  C07K16/28 ,  C07K16/30 ,  A61K31/7068 ,  A61K39/395 ,  A61K45/06 ,  C07K16/10 ,  C07K16/22

CPC classification number: C07K16/2827 ,  A61K31/7068 ,  A61K39/00 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/1063 ,  C07K16/22 ,  C07K16/28 ,  C07K16/30 ,  C07K16/3046 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/71 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2317/92 ,  Y02A50/41 ,  Y02A50/412 ,  Y02A50/423 ,  Y02A50/492 ,  A61K2300/00

Abstract: The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.

公开(公告)号：US10570213B2

公开(公告)日：2020-02-25

申请号：US15167125

申请日：2016-05-27

Applicant: Genentech, Inc.

Inventor： Jeong Kim ,  Jeanne Cheung

IPC: C07K16/28 ,  A61K39/395 ,  C07K16/32 ,  A61K31/337 ,  A61K45/06 ,  A61K31/282 ,  C07K16/30 ,  A61K39/00

Abstract: The invention provides methods and compositions for treating cancer and for enhancing immune function in an individual having cancer. The methods comprise administering a PD-1 axis binding antagonist and a taxane.